Millennium Oncology — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$57,225	3
2021	Research	$175,965	15
2020	Research	$370,717	23
2019	Research	$490,505	5

Breakdown

Who paid Research payments · program years 2019–2022

Array BioPharma Inc. $541,997 34 payments
Novartis Pharmaceuticals Corporation $462,235 4 payments
Takeda Pharmaceuticals U.S.A., Inc. $57,225 3 payments
Amgen Inc. $32,785 2 payments
EMD Serono, Inc. $170 3 payments

Studies the money was for Research payments · program years 2019–2022

An Open Label Multicenter Phase Iiib Study of Ribociclib Lee011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive HR Her2 Negative Her2 Advanced Breast Cancer Abc Who Received No Prior Hormonal Therapy $457,020 2 payments
A Phase 2 Openlabel Study of Encorafenib Binimetinib in Patients With Brafv600emutant Nonsmall Cell Lung Cancer $366,202 22 payments
A Phase 2 Openlabel Study of Encorafenib Binimetinib in Patients With Brafv600mutant Nonsmall Cell Lung Cancer $175,795 12 payments
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (Ninlaro?) in Combination With Lenalidomide and Dexamethasone (Ird) in Patients With Multiple Myeloma Previously Receiving A Bortezomib-Based Induction Regimen (US Mm-6) $57,225 3 payments
Modified Kd56 Regimen in US Community Centers $32,785 2 payments
Ribociclib + Standard Endocrine Therapy in Patients With Hr+Her2-Early BC at High Risk for Recurrence $4,514 1 payment
Monaleesa 3 A Randomized Double Blind Placebocontrolled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Postmenopausal Women With Hormone Receptor Positive Her2 Negative Advanced Breast Cancer Who Have Received No Or Only One Line $700 1 payment
A Phase II, open-label, single-arm study ofberzosertib (M6620) in combination withtopotecan in participants with relapsedplatinum-resistant small-cell lung cancer $170 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.